Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis

Annals of Clinical Microbiology and Antimicrobials

Volumn 4, Issue , 2005, Pages

  Sethi, Sanjay ^a   Anzueto, Antonio ^b   Farrell, David J ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c GR Micro   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAMASE; CEFUROXIME; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; METICILLIN; PENICILLIN G; TELITHROMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT; KETOLIDE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CHRONIC BRONCHITIS; CONTROLLED STUDY; DISEASE EXACERBATION; EMPIRICISM; ENZYME SYNTHESIS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEALTH CENTER; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; ADULT; AGED; BACTERIUM; DRUG EFFECT; FEMALE; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIA; BRONCHITIS, CHRONIC; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; KETOLIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 26944453219     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-4-5     Document Type: Article

References (44)

1. WHO: The World Health Report 2002. Reducing risks, promoting healthy life. Volume MDI.WHR.202.A. Geneva, The World Health Organization; 2002.
2. Gross NJ: The GOLD standard for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(5):1047-1048.
3. GOLD: Global Initiative for Chronic Obstructive Lung Disease. http://wwwgoldcopdcom/ 2003.
4. ATS: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995, 152(5 Pt 2):S77-121.
5. Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH: Role of infection in chronic bronchitis. Am Rev Respir Dis 1976, 113(4):465-474.
6. Buscho RO, Saxtan D, Shultz PS, Finch E, Mufson MA: Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis 1978, 137(4):377-383.
7. Smith CB, Golden CA, Kanner RE, Renzetti ADJ: Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980, 121(2):225-232.
8. Blasi F, Legnani D, Lombardo VM, Negretto GG, Magliano E, Pozzoli R, Chiodo F, Fasoli A, Allegra L: Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993, 6(1):19-22.
9. Miyashita N, Niki Y, Nakajima M, Kawane H, Matsushima T: Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD. Chest 1998, 114(4):969-971.
10. Sethi S: Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother 1999, 43 Suppl A:97-105.
11. Saint S, Bent S, Vittinghoff E, Grady D: Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. Jama 1995, 273(12):957-960.
12. Allegra L, Blasi F, de Bernardi B, Cosentini R, Tarsia P: Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther 2001, 14(2):149-155.
13. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA: Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease. Annals of Internal Medicine 1987, 106:196-204.
14. Wilson R, Schentag JJ, Ball P, Mandell L: A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002, 24(4):639-652.
15. Spencer S, Jones PW, Group GLOBES: Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003, 58(7):589-593.
16. Sethi S, Murphy TF: Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001, 14(2):336-363.
17. Destache CJ: Optimizing economic outcomes in acute exacerbations of chronic bronchitis. Pharmacotherapy 2002, 22(1 Pt 2):12S-17S; discussion 30S-32S.
18. Hoban D, Felmingham D: The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother 2002, 50 Suppl S1:49-59.
19. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN: The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003, 52(2):229-246.
20. Douthwaite S, Hansen LH, Mauvais P: Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 2000, 36(1):183-193.
21. Zhong P, Shortridge VD: The role of efflux in macrolide resistance. Drug Resist Updat 2000, 3(6):325-329.
22. Farrell DJ, Morrissey I, Bakker S, Felmingham D: Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002, 50 Suppl S1:39-47.
23. Farrell DJ, Douthwaite S, Morrissey I, Bakker S, Poehlsgaard J, Jakobsen L, Felmingham D: Macrolide Resistance by Ribosomal Mutation in Clinical Isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 Study. Antimicrob Agents Chemother 2003, 47(6):1777-1783.
24. Felmingham D: The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002, 50(90002):1-7.
25. NCCLS: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard - Fifth Edition. NCCLS document M7 - A5. Wayne, Pennsylvania 19087 - 1898, USA; 2000.
26. NCCLS: Performance standards antimicrobial susceptibility testing; Twelfth information supplement. NCCLS document M100 - 12. Wayne, Pennsylvania 19807 - 1898, USA, NCCLS; 2002.
27. NCCLS: Performance standards antimicrobial susceptibility testing; Twelfth information supplement. NCCLS document M100-S14. Wayne, Pennsylvania 19807 - 1898, USA, NCCLS; 2004.
28. Sethi S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000, 117(5 Suppl 2):380S-5S.
29. Tager I, Speizer FE: Role of infection in chronic bronchitis. N Engl J Med 1975, 292(11):563-571.
30. Murphy TF, Sethi S: Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992, 146(4):1067-1083.
31. Isada CM: Pro: antibiotics for chronic bronchitis with exacerbations. Semin Respir Infect 1993, 8(4):243-253.
32. Sethi S: The Role of Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Curr Infect Dis Rep 2003, 5(1):9-15.
33. Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002, 347(7):465-471.
34. Moellering RCJ: Meeting the challenges of beta-lactamases. J Antimicrob Chemother 1993, 31 Suppl A:1-8.
35. Scheld WM: Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003, 9(1):1-9.
36. Nord CE, Farrell DJ, Leclercq R: Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections. Microb Drug Resist 2004, 10(3):255-263.
37. Miyashita N, Fukano H, Niki Y, Matsushima T: In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 2001, 48(3):403-405.
38. Edelstein PH, Edelstein MA: In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999, 43(1):90-95.
39. Hammerschlag MR, Roblin PM, Bebear CM: Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J Antimicrob Chemother 2001, 48 Suppl T1:25-31.
40. Khair OA, Andrews JM, Honeybourne D, Jevons G, Vacheron F, Wise R: Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001, 47(6):837-840.
41. Nicolau DP: Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 2001, 29 Suppl 2:11-15.
42. Edlund C, Alvan G, Barkholt L, Vacheron F, Nord CE: Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother 2000, 46(5):741-749.
43. Aubier M, Aldons PM, Leak A, McKeith DD, Leroy B, Rangaraju M, Bienfait-Beuzon C: Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002, 96(11):862-871.
44. Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ: The ketolides: a critical review. Drugs 2002, 62(12):1771-1804.